(NASDAQ: LGND) Ligand Pharmaceuticals's forecast annual revenue growth rate of 15.49% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 106.08%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 24.86%.
Ligand Pharmaceuticals's revenue in 2025 is $187,584,000.On average, 10 Wall Street analysts forecast LGND's revenue for 2025 to be $4,291,646,640, with the lowest LGND revenue forecast at $3,944,003,666, and the highest LGND revenue forecast at $4,541,306,814. On average, 9 Wall Street analysts forecast LGND's revenue for 2026 to be $4,861,514,605, with the lowest LGND revenue forecast at $4,328,292,207, and the highest LGND revenue forecast at $5,411,590,044.
In 2027, LGND is forecast to generate $5,715,924,621 in revenue, with the lowest revenue forecast at $5,053,560,893 and the highest revenue forecast at $6,603,060,892.